How does each substituent functional group of oseltamivir lose its activity against virulent H5N1 influenza mutants?

Biophysical Chemistry

Volumn 145, Issue 1, 2009, Pages 29-36

  Rungrotmongkol, Thanyada ^a,b   Udommaneethanakit, Thanyarat ^b   Malaisree, Maturos ^a   Nunthaboot, Nadtanet ^c   Intharathep, Pathumwadee ^a   Sompornpisut, Pornthep ^a   Hannongbua, Supot ^a,b  

^a Faculty of Science   (Thailand)

^b CHULALONGKORN UNIVERSITY   (Thailand)

^c MAHASARAKHAM UNIVERSITY   (Thailand)

Author keywords

H274Y; H5N1; Molecular dynamics simulations; N294S; Oseltamivir resistance

Indexed keywords

AMMONIA; ASPARAGINE; FUNCTIONAL GROUP; GLUTAMIC ACID; HISTIDINE; HYDROGEN; LYSINE; OSELTAMIVIR; SERINE; TYROSINE;

ANALYTIC METHOD; ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; DRUG IDENTIFICATION; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG STRUCTURE; DRUG TARGETING; HYDROGEN BOND; HYDROPHOBICITY; INFLUENZA VIRUS A H5N1; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; STRUCTURE ANALYSIS; VIRUS MUTANT; VIRUS VIRULENCE;

AMINO ACID SUBSTITUTION; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA A VIRUS, H5N1 SUBTYPE; MOLECULAR CONFORMATION; MUTATION; OSELTAMIVIR; VIRULENCE;

EID: 70349251134     PISSN: 03014622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bpc.2009.08.006     Document Type: Article

References (30)

1. Ferraris O., and Lina B. Mutations of neuraminidase implicated in neuraminidase inhibitors resistance. J. Clin. Virol. 41 (2008) 13-19
2. Collins P.J., Haire L.F., Lin Y.P., Liu J., Russell R.J., Walker P.A., Skehel J.J., Martin S.R., Hay A.J., and Gamblin S.J. Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants. Nature 453 (2008) 1258-1261
3. Ives J.A., Carr J.A., Mendel D.B., Tai C.Y., Lambkin R., Kelly L., Oxford J.S., Hayden F.G., and Roberts N.A. The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. Antivir. Res. 55 (2002) 307-317
4. Wang M.Z., Tai C.Y., and Mendel D.B. Mechanism by which mutations at His274 alter sensitivity of influenza A virus N1 neuraminidase to oseltamivir carboxylate and zanamivir. Antimicrob. Agents Chemother. 46 (2002) 3809-3816
5. Kiso M., Mitamura K., Sakai-Tagawa Y., Shiraishi K., Kawakami C., Kimura K., Hayden F.G., Sugaya N., and Kawaoka Y. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 364 (2004) 759-765
6. Mishin V.P., Hayden F.G., and Gubareva L.V. Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors. Antimicrob. Agents Chemother. 49 (2005) 4515-4520
7. de Jong M.D., Tran T.T., Truong H.K., Vo M.H., Smith G.J., Nguyen V.C., Bach V.C., Phan T.Q., Do Q.H., Guan Y., Peiris J.S., Tran T.H., and Farrar J. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N. Engl. J. Med. 353 (2005) 2667-2672
8. Le Q.M., Kiso M., Someya K., Sakai Y.T., Nguyen T.H., Nguyen K.H., Pham N.D., Ngyen H.H., Yamada S., Muramoto Y., Horimoto T., Takada A., Goto H., Suzuki T., Suzuki Y., and Kawaoka Y. Avian flu: isolation of drug-resistant H5N1 virus. Nature 437 (2005) 1108
9. Yen H.L., Ilyushina N.A., Salomon R., Hoffmann E., Webster R.G., and Govorkova E.A. Neuraminidase inhibitor-resistant recombinant A/Vietnam/1203/04 (H5N1) influenza viruses retain their replication efficiency and pathogenicity in vitro and in vivo. J. Virol. 81 (2007) 12418-12426
10. De Clercq E. Antiviral agents active against influenza A virus. Nat. Rev. Drug Discov. 5 (2007) 1015-1025
11. von Itzstein M. The war against influenza: discovery and development of sialidase inhibitors. Nat. Rev. Drug Discov. 6 (2007) 967-974
12. Schünemann H.J., Hill S.R., Kakad M., Bellamy R., Uyeki T.M., Hayden F.G., Yazdanpanah Y., Beigel J., Chotpitayasunondh T., Del Mar C., Farrar J., Hien T.T., Özbay B., Sugaya N., Fukuda K., Shindo N., Stockman L., Vist G.E., Croisier A., Nagjdaliyev A., Roth C., Thomson G., Zucker H., and Oxman A.D. WHO rapid advice guidelines for pharmacological management of sporadic human infection with avian influenza A (H5N1) virus. Lancet Infect. Dis. 7 (2007) 21-31
13. Russell R.J., Haire L.F., Stevens D.J., Collins P.J., Lin Y.P., Blackburn G.M., Hay A.J., Gamblin S.J., and Skehel J.J. The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. Nature 443 (2006) 45-49
14. M. Malaisree, T. Rungrotmongkol, N. Nunthaboot, O. Aruksakunwong, P. Intharathep, P. Decha, P. Sompornpisut, S. Hannongbua, Source of oseltamivir resistance in avian influenza H5N1 virus with the H274Y mutation, Amino Acids (2009), doi:10.1007/s00726-008-0201-z.
15. Marelius J., Kolmodin K., Feierberg I., and Åqvist J. Q: a molecular dynamics program for free energy calculations and empirical valence bond simulations in biomolecular systems. J. Mol. Graph. Model. 16 (1998) 213-225
16. Case D.A., Pearlman D.A., Caldwell J.W., Cheatham III T.E., Wang J., Ross W.S., Simmerling C.L., Darden T.A., Merz K.M., Stanton R.V., Cheung A.L., Vincent J.J., Crowley M., Tsui V., Gohike H., Radmer R.J., Duan Y., Pitera J., Massova I., Seibel G.L., Singh U.C., Weiner P.K., and Kollman P.A. AMBER 7 (2002), University of California, San Francisco, CA
17. Malaisree M., Rungrotmongkol T., Decha P., Intharathep P., Aruksakunwong O., and Hannongbua S. Understanding of known drug-target interactions in the catalytic pocket of neuraminidase subtype N1. Proteins 71 (2008) 1908-1918
18. Jorgensen W.L., Chandrasekhar J., Madura J.D., Impey R.W., and Klein M.L. Comparison of simple potential functions for simulating liquid water. J. Chem. Phys. 79 (1983) 926-935
19. Li H., Robertson A.D., and Jensen J.H. Very fast empirical prediction and interpretation of protein pKa values. Proteins 61 (2005) 704-721
20. King G., and Warshel A. A surface constrained all-atom solvent model for effective simulations of polar solutions. J. Chem. Phys. 91 (1989) 3647-3661
21. Ryckaert J.P., Ciccotti G., and Berendsen H.J.C. Numerical integration of the Cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes. J. Chem. Phys. 23 (1997) 327-341
22. Hansson T., and Åqvist J. Estimation of binding free energies for HIV proteinase inhibitors by molecular dynamics simulations. Protein Eng. 8 (1995) 1137-1144
23. Åqvist J., Medina C., and Samuelsson J.E. A new method for predicting binding-affinity in computer-aided drug design. Protein Eng. 7 (1994) 385-391
24. Wall I.D., Leach A.R., Salt D.W., Ford M.G., and Essex J.W. Binding constants of neuraminidase inhibitors: an investigation of the linear interaction energy method. J. Med. Chem. 42 (1999) 5142-5152
25. Abed Y., Nehmé B., Baz M., and Boivin G. Activity of the neuraminidase inhibitor A-315675 against oseltamivir-resistant influenza neuraminidases of N1 and N2. Antivir. Res. 77 (2007) 163-166
26. Aruksakunwong O., Malaisree M., Decha P., Sompornpisut P., Parasuk V., Pianwanit S., and Hannongbua S. On the lower susceptibility of oseltamivir to influenza neuraminidase subtype N1 than those in N2 and N9. Biophys. J. 92 (2007) 798-807
27. Colman P.M., Varghese J.N., and Laver W.G. Structure of the catalytic and antigenic sites in influenza virus neuraminidase. Nature 303 (1983) 41-44
28. McKimm-Breschkin J.L., Sahasrabudhe A., Blick T.J., and McDonald M. Mechanisms of resistance of influenza virus to neuraminidase inhibitors. Int. Congr. Ser. 1219 (2001) 855-861
29. Moscona A. Oseltamivir resistance-disabling our influenza defenses. N. Engl. J. Med. 353 (2005) 2633-2636
30. N.X. Wang, J.J. Zheng, Computational studies of H5N1 influenza virus resistance to oseltamivir. Protein Sci. 18:707-715.